Abeona Therapeutics Inc. announced on July 15, 2025, the activation of Lucile Packard Children’s Hospital Stanford as its newest Qualified Treatment Center (QTC) for FDA-approved ZEVASKYN™ (prademagene zamikeracel) gene-modified cellular sheets. This marks the second QTC to become operational, expanding access to this first-of-its-kind therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). Lucile Packard Children’s Hospital Stanford has completed all necessary QTC start-up activities and is ready to accept patients.
This site activation is a key milestone in Abeona's commercial launch, building on the earlier activation of Lurie Children’s Hospital of Chicago. ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application, offering profound new hope for patients battling this painful skin disorder. The collaboration with Stanford Medicine, where the technology originated, spans two decades of research.
Abeona continues to commit to enabling access to ZEVASKYN for eligible patients in the U.S. through its comprehensive patient support program, Abeona Assist™. The expansion of the QTC network is crucial for increasing patient identification and treatment initiation, supporting the ramp-up of ZEVASKYN sales across the country.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.